Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 556 | 574 | 684 | 763 | 872 | 952 | 1,029 | 1,122 |
| Operating profit | €m | 139 | 150 | ||||||
| Net profit | €m | 60 | 61 | 70 | 71 | 81 | 91 | 92 | 105 |
| EPS reported | € | 1.24 | 1.25 | ||||||
| Operating cashflow per share | € | 1.76 | 1.87 | ||||||
| Capex per share | € | 0.21 | 0.25 | ||||||
| FCF per share | € | 1.55 | 1.62 | ||||||
| Free cash flow | €m | 113 | 119 | ||||||
| Net debt | €m | 227 | 505 | ||||||
| Book value equity | €m | 552 | 595 | ||||||
| Book value per share | € | 7.51 | 8.09 | ||||||
| Number of shares | m | 73.4 | 73.47 | ||||||
| DPS (TTM paid) | € | 0.40 | 0.40 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 17.18 | - | ||||||
| P/B LTM | x | 2.82 | 2.78 | ||||||
| P/S LTM | x | 1.63 | 1.60 | ||||||
| P/FCF LTM | x | 13.77 | 13.91 | ||||||
| EV/EBITDA LTM | x | 10.03 | 10.73 | ||||||
| EV/Sales LTM | x | 1.93 | 2.10 | ||||||
| Earnings Yield LTM | % | 5.82% | 5.56% | ||||||
| FCF Yield | % | 7.26% | 7.19% | ||||||
| Quality | |||||||||
| ROE | % | 16.50% | 16.01% | ||||||
| ROIC | % | 10.48% | 9.42% | ||||||
| Operating margin | % | 14.64% | 14.60% | ||||||
| Gross margin | % | 21.50% | 37.31% | ||||||
| FCF/Sales | % | 11.87% | 11.53% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +12.73% | +6.84% | ||||||
| Sales Growth YoY | % | +9.20% | +11.95% | ||||||
| Net Income Growth YoY | % | +12.99% | +7.06% | ||||||
| FCF Growth | % | +35.10% | +19.14% | ||||||
| Operating Profit Growth | % | +6.67% | +7.09% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 1.67% | 1.79% | ||||||
| Dividend Growth | % | +14.29% | +14.29% | ||||||
| Payout Ratio | % | 28.57% | 28.57% | ||||||
| FCF/Debt | x | 0.24 | 0.19 | ||||||
| Net Debt/EBITDA | x | 1.55 | 2.52 | ||||||
| EBIT/Net interest | x | 4.27 | 4.40 | ||||||
| Net debt/market cap | % | 14.61% | 30.63% | ||||||
| Net debt/Equity | x | 0.41 | 0.85 | ||||||
| Gross debt/equity | x | 0.85 | 1.07 | ||||||
ETFs that hold Fagron
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| abrdn International Small Cap Active ETF | ASCI | 9 | 3.02% |
Funds with Fagron among their ten largest holdings, largest fund first.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Fagron N.V. operates as a pharmaceutical compounding enterprise, dedicated to providing customized medicinal solutions for hospitals, pharmacies, clinics, and individual patients. The company is actively involved in developing innovative concepts, delivery systems, and formulations within the compounding sector. Its extensive offerings encompass essential raw materials, specialized equipment, semi-finished products, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Additionally, through the Fagron Academy, the firm delivers educational and training programs to healthcare prescribers and pharmacists. With a significant global footprint, Fagron conducts operations across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company adopted its current name, Fagron NV, in January 2015, having previously been known as Arseus NV.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| abrdn International Small Cap Active ETF | ASCI | 9 | 3.02% |
Funds with Fagron among their ten largest holdings, largest fund first.
Based on consensus from external analysts. Not Kvantra's opinion.
Fagron N.V. operates as a pharmaceutical compounding enterprise, dedicated to providing customized medicinal solutions for hospitals, pharmacies, clinics, and individual patients. The company is actively involved in developing innovative concepts, delivery systems, and formulations within the compounding sector. Its extensive offerings encompass essential raw materials, specialized equipment, semi-finished products, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Additionally, through the Fagron Academy, the firm delivers educational and training programs to healthcare prescribers and pharmacists. With a significant global footprint, Fagron conducts operations across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company adopted its current name, Fagron NV, in January 2015, having previously been known as Arseus NV.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free